The global benign prostatic hyperplasia treatment devices market accounted for USD 1.60 billion in 2023 and is expected to reach at USD 4.11 billion by 2034 with a CAGR of 8.94% during the forecast period 2024-2034. The market will develop as a result of rising rates of benign prostatic hyperplasia, technological advancements, growing patient preference for minimally invasive procedures, and strategic alliances and collaborations.
The prostate gland's expansion is the source of benign prostatic hyperplasia, a frequent condition among older men. BPH is more common in older people, and as the world's population ages, more men are anticipated to receive BPH diagnoses. The need for therapeutic devices will rise as a result of this. For instance, Boston Scientific declared in January 2023 that patient recruitment in its clinical trial assessing the use of its Rezūm System for the treatment of benign prostatic hyperplasia (BPH) has concluded.
By treatment, the minimally invasive surgery segment accounted for the highest revenue-grossing segment in the global benign prostatic hyperplasia treatment devices market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the increasing preference for less invasive procedures, shorter recovery times, and reduced risk of complications compared to traditional surgical methods. For instance, Intuitive Surgical announced in November 2022 that it had successfully acquired Auris Health, Inc., a firm that develops robotic technologies for medical treatments, including urology.
By product, the resectoscopes segment accounted for the highest revenue-grossing segment in the global benign prostatic hyperplasia treatment devices market in 2023 owing to the high demand for transurethral resection procedures, which are considered the gold standard for treating BPH, along with the widespread availability and utilization of resectoscopes in urological surgeries globally. For instance, Lumenis stated in September 2022 that their MOSES 2.0 Technology would be available for use in urological operations, such as BPH treatments. Additionally, the urology laser segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of laser technologies in various urological procedures, including those for benign prostatic hyperplasia treatment, due to their precision, minimal invasiveness, shorter recovery times, and favorable patient outcomes.
By procedure, the transurethral resection of the prostate (TURP) segment accounted for the highest revenue-grossing segment in the global benign prostatic hyperplasia treatment devices market in 2023 owing to the established efficacy, widespread adoption, and long-standing history of use as a standard surgical treatment for BPH, particularly in regions where access to advanced technologies or alternatives may be limited. For instance, the FDA approved Medtronic's UroLift System in December 2022 for the treatment of benign prostatic hyperplasia (BPH). Additionally, the robot-assisted laparoscopic prostatectomy (RASP) segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of robotic-assisted surgical systems for their benefits such as improved surgical precision, shorter hospital stays, faster recovery times, and better outcomes for patients undergoing prostatectomy procedures.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global benign prostatic hyperplasia treatment devices market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of benign prostatic hyperplasia (BPH) and related urinary symptoms, rising adoption of advanced treatment devices and procedures in hospital settings, and growing healthcare infrastructure supporting urological care, particularly in emerging economies. For instance, Teleflex said in August 2022 that the FDA has approved its UroLift System for the management of benign prostatic hyperplasia (BPH).
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of benign prostatic hyperplasia (BPH), advanced healthcare infrastructure, favorable reimbursement policies, increasing adoption of minimally invasive treatment options, and continuous technological advancements in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising geriatric population, increasing prevalence of benign prostatic hyperplasia (BPH), improving healthcare infrastructure, expanding access to advanced medical technologies, and growing adoption of minimally invasive treatment options in the region. For instance, in May 2022, the FDA of the United States approved OmniGuide Holdings' hybrid thulium laser therapy device, RevoLix HTL.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
The prostate gland's expansion is the source of benign prostatic hyperplasia, a frequent condition among older men. BPH is more common in older people, and as the world's population ages, more men are anticipated to receive BPH diagnoses. The need for therapeutic devices will rise as a result of this. For instance, Boston Scientific declared in January 2023 that patient recruitment in its clinical trial assessing the use of its Rezūm System for the treatment of benign prostatic hyperplasia (BPH) has concluded.
By treatment, the minimally invasive surgery segment accounted for the highest revenue-grossing segment in the global benign prostatic hyperplasia treatment devices market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the increasing preference for less invasive procedures, shorter recovery times, and reduced risk of complications compared to traditional surgical methods. For instance, Intuitive Surgical announced in November 2022 that it had successfully acquired Auris Health, Inc., a firm that develops robotic technologies for medical treatments, including urology.
By product, the resectoscopes segment accounted for the highest revenue-grossing segment in the global benign prostatic hyperplasia treatment devices market in 2023 owing to the high demand for transurethral resection procedures, which are considered the gold standard for treating BPH, along with the widespread availability and utilization of resectoscopes in urological surgeries globally. For instance, Lumenis stated in September 2022 that their MOSES 2.0 Technology would be available for use in urological operations, such as BPH treatments. Additionally, the urology laser segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of laser technologies in various urological procedures, including those for benign prostatic hyperplasia treatment, due to their precision, minimal invasiveness, shorter recovery times, and favorable patient outcomes.
By procedure, the transurethral resection of the prostate (TURP) segment accounted for the highest revenue-grossing segment in the global benign prostatic hyperplasia treatment devices market in 2023 owing to the established efficacy, widespread adoption, and long-standing history of use as a standard surgical treatment for BPH, particularly in regions where access to advanced technologies or alternatives may be limited. For instance, the FDA approved Medtronic's UroLift System in December 2022 for the treatment of benign prostatic hyperplasia (BPH). Additionally, the robot-assisted laparoscopic prostatectomy (RASP) segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of robotic-assisted surgical systems for their benefits such as improved surgical precision, shorter hospital stays, faster recovery times, and better outcomes for patients undergoing prostatectomy procedures.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global benign prostatic hyperplasia treatment devices market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of benign prostatic hyperplasia (BPH) and related urinary symptoms, rising adoption of advanced treatment devices and procedures in hospital settings, and growing healthcare infrastructure supporting urological care, particularly in emerging economies. For instance, Teleflex said in August 2022 that the FDA has approved its UroLift System for the management of benign prostatic hyperplasia (BPH).
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of benign prostatic hyperplasia (BPH), advanced healthcare infrastructure, favorable reimbursement policies, increasing adoption of minimally invasive treatment options, and continuous technological advancements in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising geriatric population, increasing prevalence of benign prostatic hyperplasia (BPH), improving healthcare infrastructure, expanding access to advanced medical technologies, and growing adoption of minimally invasive treatment options in the region. For instance, in May 2022, the FDA of the United States approved OmniGuide Holdings' hybrid thulium laser therapy device, RevoLix HTL.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Treatment, Procedure, Product, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Benign Prostatic Hyperplasia Treatment Devices Market Report 2023 - 2034
Benign Prostatic Hyperplasia Treatment Devices Market Analysis & Forecast by Treatment 2023 - 2034 (Revenue USD Bn)
- Minimal Invasive Surgery
- Invasive Surgery
Benign Prostatic Hyperplasia Treatment Devices Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Resectoscopes
- Urology Laser
- Radiofrequency Ablation
- Electrodes
- Catheters
- Prostatic Stents
- Implants
Benign Prostatic Hyperplasia Treatment Devices Market Analysis & Forecast by Procedure 2023 - 2034 (Revenue USD Bn)
- Transurethral Resection of The Prostate
- Prostate Laser Surgery
- Transurethral Microwave Thermotherapy
- Transurethral Needle Ablation Of The Prostate
- Prostatic Urethral Lift
- Water Vapor Therapy
- Robot-assisted Laparoscopic Prostatectomy
- Aquablation Therapy
- Prostatic Artery Embolization
- Open Prostatectomy
- Bipolar Enucleation Of Prostate
- Transurethral Incision Of The Prostate
- High-Intensity Focused Ultrasound
- Others
Benign Prostatic Hyperplasia Treatment Devices Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Specialty Facilities
- Research & Manufacturing
Benign Prostatic Hyperplasia Treatment Devices Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Benign Prostatic Hyperplasia Treatment Devices Market: Treatment Estimates & Trend Analysis
8. Benign Prostatic Hyperplasia Treatment Devices Market: Product Estimates & Trend Analysis
9. Benign Prostatic Hyperplasia Treatment Devices Market: Procedure Estimates & Trend Analysis
10. Benign Prostatic Hyperplasia Treatment Devices Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Benign Prostatic Hyperplasia Treatment Devices Market
13. Europe Global Benign Prostatic Hyperplasia Treatment Devices Market
14. Asia Pacific Global Benign Prostatic Hyperplasia Treatment Devices Market
15. Latin America Global Benign Prostatic Hyperplasia Treatment Devices Market
16. MEA Global Benign Prostatic Hyperplasia Treatment Devices Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Boston Scientific Corporation
- Teleflex Incorporated
- Olympus Corporation
- KARL STORZ SE & Co. KG
- Medtronic plc
- Cook Medical LLC
- Urologix LLC
- Lumenis Ltd.
- Richard Wolf GmbH
- Intuitive Surgical Inc.
- ROCAMED
- SRS Medical Systems Inc.
- Cogentix Medical (A Subsidiary of LABORIE)
- Biolitec AG
- PROCEPT BioRobotics Corporation.
